Medvi vs Fridays: Compounded GLP-1 Programs Compared

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This entry in the PlexusDx Education Hub examines GLP-1 telehealth through a specific lens: two programs that share almost the same operating model. Browse all Peptides & GLP-1 education

What follows is an independent editorial review. PlexusDx has no financial or commercial relationship with Medvi, Fridays, or their parent companies, and no affiliate arrangements shaped this article.

Full head-to-head: PlexusDx vs Fridays →

Full head-to-head: PlexusDx vs MEDVi →

Medvi and Fridays are unusual among comparison searches because their models are so close: both wrap telehealth around a compounded-pharmacy pathway. When two services look nearly identical on paper, the useful questions shift to how compounding actually works, who provides oversight, and what the numbers really say. Current as of April 2026.

Why Medvi and Fridays look so similar

Medvi Wellness and Fridays Health both operate as telehealth plus a compounded-pharmacy pathway, which is why they surface together in searches. Each typically offers a virtual clinical review, a provider-issued prescription, and dispensing of compounded semaglutide or tirzepatide. Confirm current program details at Medvi's official website and Fridays's official website.

The 503A compounding pathway, explained

Compounded GLP-1 medication is prepared by a state-licensed 503A compounding pharmacy for an individual patient's prescription, rather than mass-manufactured as an FDA-approved brand product. Both Medvi and Fridays route into this pathway. The compounded form and the branded form share the active molecule; what differs is the regulatory lane, the supply source, and how each program documents sterility and quality.

Provider oversight and how prescriptions get written

In either program a licensed clinician reviews the intake before a prescription is issued. The variables worth checking are provider type (physician versus nurse practitioner or physician assistant), the depth of follow-up during dose titration, and how side-effect management is handled. These operational details, more than branding, distinguish two otherwise similar compounding-forward services.

Reading the two price sheets

Fridays publishes month-to-month rates of $249/mo for compounded semaglutide and $359/mo for compounded tirzepatide (joinfridays.com/pricing, verified 2026-07-20), bundled with zero membership dues, free shipping, coaching, and dietitian access; committing to a prepaid year trims the effective cost to roughly $150/mo and $240/mo respectively. Fridays' rates moved materially within a single day, so verify before committing. Medvi posts its own pricing separately. As a benchmark, PlexusDx runs about $60–$70/mo below Fridays' month-to-month on both compounds, while Fridays' prepaid 3- and 6-month bundles land lower per month.

What the GLP-1 trials actually established

Because both programs dispense the same compound class, the evidence base is shared. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide were studied in the STEP program (semaglutide, weight management, NEJM 2021), the SURMOUNT program (tirzepatide, weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide, obstructive sleep apnea, NEJM 2024). Outcomes follow the compound and dose, not the compounding pharmacy behind them.

The upstream signal both programs skip

Neither Medvi nor Fridays looks at the inherited biology framing a GLP-1 response. Variants in FTO (linked to fat mass and obesity risk), GLP1R (which encodes the GLP-1 receptor itself), MC4R (central to appetite and energy balance), and TCF7L2 (involved in glucose regulation and incretin secretion) map the metabolic baseline a clinician works from. These are pathway-level markers that do not predict compound-specific response but do describe your underlying biology. PlexusDx builds that context in: the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights spanning FTO, MC4R, and TCF7L2, alongside its own Weight Management Protocols — offered as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Test first, then invest in a protocol with your provider.

No affiliation: PlexusDx is independent of Medvi and holds no commercial relationship with any company reviewed above.

More from the PlexusDx Education Hub: What Is GLP 1, GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs.

Editorial disclaimer: this piece is educational and not a buying recommendation. PlexusDx is not affiliated with Medvi and offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before starting any peptide protocol.

Weigh the alternative: browse the Weight Management Protocols, or start with the Precision Peptide Genetic Test to understand your GLP-1 pathway biology first.

Frequently Asked Questions

Are Medvi and Fridays essentially the same program?

They share a model — telehealth plus a compounded-pharmacy pathway — but differ in provider type, pricing tiers, follow-up depth, and pharmacy partner. The similarity is structural, not identical. Compare each brand's credentialing, medication menu, and support directly on its own site before deciding which fits your situation.

Is compounded GLP-1 medication legitimate?

Compounded semaglutide and tirzepatide are prepared by state-licensed 503A compounding pharmacies for an individual prescription. That pathway is distinct from FDA-approved brand manufacturing. Legitimacy hinges on licensed clinicians, a properly licensed pharmacy, and clinical evaluation before prescribing, so verify those specifics for either program you consider.

Does the Precision Peptide Genetic Test predict how a compound will work?

No. It does not forecast response to any compounded medication, brand, or telehealth service. It reads pathway-level variants in FTO and MC4R, and TCF7L2 that describe baseline GLP-1 biology — upstream context that stays relevant whether the prescription is compounded or a branded product.

How does the PlexusDx model differ from Medvi and Fridays?

PlexusDx dispenses its own semaglutide and tirzepatide protocols and pairs them with the Precision Peptide Genetic Test. The distinguishing element is pathway-level genetic insight into FTO, MC4R variants — context that compounding-forward services like Medvi and Fridays do not put beside the medication.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.